H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)’s Carvykti Despite Sales Miss

TheFly reported connected January 22 that H.C. Wainwright lowered LEGN’s terms people to $50 from $60 but kept a Buy rating, noting Q4 Carvykti sales of $555M missed the $582M consensus. They presumption the caller pullback arsenic a buying accidental and highlighted Carvykti’s curative potential.

Similarly, a time earlier connected January 21, TD Cowen downgraded Legend Biotech Corporation (NASDAQ:LEGN) from Buy to Hold and chopped the terms people to $21 from $62. The steadfast said Carvykti’s Q4 income of $555 cardinal versus the $582 cardinal statement reflected vacation seasonality but besides indicated sluggish demand, which is influenced by toxicity concerns and increasing competition. These factors person slowed adoption successful the assemblage and constricted uptake adjacent successful world centers.

Legend Biotech Corporation (NASDAQ:LEGN) is simply a planetary biotechnology institution focused connected processing and commercializing precocious compartment therapies, particularly CAR‑T treatments for cancer, similar CARVYKTI for aggregate myeloma. It collaborates with partners similar Johnson & Johnson and builds end‑to‑end capabilities from find to manufacturing to grow therapeutic impact.

While we admit the imaginable of LEGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.